熱門資訊> 正文
Invivyd报告PEMGARDA对主要SARS-CoV-2变体KP.3.1.1和LB.1的持续中和作用
2024-09-03 19:29
- New pseudovirus in vitro neutralization data show continued neutralizing activity of PEMGARDA™ (pemivibart) against KP.3.1.1, LB.1, and other SARS-CoV-2 variants tested
- Center for Disease Control reports KP.3.1.1 is the only major variant increasing in proportionality nationally
- Variants confirmed as susceptible to pemivibart in independent analyses contain key Q493E, s31del, and other mutations that are prominent in circulating SARS-CoV-2 variants
- Data submitted to FDA for anticipated timely updates to PEMGARDA™ Fact Sheet
- Pipeline candidate VYD2311 shows attractive neutralization potency against the same contemporary viruses
推薦文章
風險及免責提示：以上內容僅代表作者的個人立場和觀點，不代表華盛的任何立場，華盛亦無法證實上述內容的真實性、準確性和原創性。投資者在做出任何投資決定前，應結合自身情況，考慮投資產品的風險。必要時，請諮詢專業投資顧問的意見。華盛不提供任何投資建議，對此亦不做任何承諾和保證。
